France-based Nanobiotix (Euronext: NANO) reports that it is partnering with Texas University of Texas MD Anderson Cancer Center for a large-scale, comprehensive clinical research collaboration to evaluate the innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. The collaboration will expand on clinical development of NBTXR3, a first-in-class agent designed to physically destroy cancer cells when activated by radiotherapy and to activate the immune system for both local control and systemic disease treatment. MD Anderson will initially conduct the launch of nine new Phase I/II clinical trials—involving approximately 340 patients—focused on evaluating the potential for clinical benefit of NBTXR3 when activated by radiotherapy, either as a monotherapy or in combination with checkpoint inhibitors. The planned trials also will look at various disease stages, including low-risk/good prognostic patients, locally advanced disease, and metastatic disease. The trials will study NBTXR3 across different radiation modalities such as radiation, re-irradiation, and compare different levels of intensity of radiation, to evaluate whether the addition of NBTXR3 to radiotherapy will improve progression-free survival, loco-regional control, quality of life and organ preservation. As part of the funding scheme for this collaboration, part of the payment will be made at the start of the collaboration. Other parts will be paid during development and the balance in case of FDA registration for a total of $12 million investment.
Formed in 2003, Nanobiotix has raised over $33 million. See the link for its pipeline.